Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | CPT2 | P23786 | 4/20 | 0.47 |
| ▸ | CPT1A | P50416 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187180 | 0.90 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1KMT2ACPT2CPT1A | |
| SCHEMBL3187156 | 0.90 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1KMT2ACPT2CPT1A | |
| SCHEMBL31710554 | 0.89 | DPP4 (0.59) | ALDH1A1KMT2AENPP2CPT2CPT1A | |
| SCHEMBL5741958 | 0.86 | KMT2A (0.65) | ALDH1A1L3MBTL1KMT2ACPT2CPT1A | |
| SCHEMBL5741952 | 0.86 | KMT2A (0.65) | ALDH1A1L3MBTL1KMT2ACPT2CPT1A | |
| SCHEMBL5743864 | 0.84 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1KMT2ACPT2CPT1A | |
| SCHEMBL3148212 | 0.84 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1KMT2ACPT2CPT1A | |
| SCHEMBL5743406 | 0.84 | L3MBTL1 (0.60) | ALDH1A1L3MBTL1KMT2ACPT2CPT1A | |
| SCHEMBL5743409 | 0.84 | L3MBTL1 (0.60) | ALDH1A1L3MBTL1KMT2ACPT2CPT1A | |
| SCHEMBL5741156 | 0.84 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1KMT2ADGAT1CPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2026042018-A1 | 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES | PFIZER INC. (US) | 2026-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | ALDH1A1 2197/4885L3MBTL1 1022/4885KMT2A 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.